• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ALDESLEUKIN Drug Record

  • Summary
  • Interactions
  • Claims
  • ALDESLEUKIN chembl:CHEMBL1201438 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    HUMAN INTERLEUKIN-2
    PROLEUKIN
    INTERLEUKIN-2 ALDESLEUKIN
    ALDESLEUKIN
    INTERLEUKIN 2

    Drug Info:

    Drug Categories lymphokines
    Drug Categories interleukins
    Drug Class antineoplastic agents
    Year of Approval 1992
    FDA Approval approved
    Drug Class recombinant protein
    Drug Indications antineoplastic agent
    Drug Categories cytochrome p-450 cyp2e1 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories drugs that are mainly renally excreted
    Drug Categories immunosuppressive agents
    Drug Categories increased lymphocyte activation
    Drug Categories increased lymphocyte cell production
    Drug Categories lymphocyte growth factor
    Drug Categories narrow therapeutic index drugs
    (2 More Sources)

    Publications:

    Shibata et al., 2007, Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations., Eur. J. Haematol.
    Fonseca et al., Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy., Scand. J. Immunol.
    Blank et al., 2006, The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells., J. Infect. Dis.
    Stauber et al., 2006, Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor., Proc. Natl. Acad. Sci. U.S.A.
    Smyth et al., 2007, Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors., Blood
    Lee et al., 2006, Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2., Oncol. Rep.
    Maclennan et al., 2006, Airway inflammation in asymptomatic children with episodic wheeze., Pediatr. Pulmonol.
    Steppan et al., 2006, Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog., J. Interferon Cytokine Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Cornish et al., 2006, Differential regulation of T-cell growth by IL-2 and IL-15., Blood
    Vlad et al., 2007, Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation., Transpl. Immunol.
    Recchia et al., 2003, Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy., J. Exp. Clin. Cancer Res.
    Ouyang et al., 1999, Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes., Arch. Toxicol.
    Liu et al., 2006, [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]., Nan Fang Yi Ke Da Xue Xue Bao
    Waldmann, 2007, Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey., J. Clin. Immunol.
    Waldmann, 2007, Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma., Oncogene
  • ALDESLEUKIN   IL2RB

    Interaction Score: 23.67

    Interaction Types & Directionality:
    agonist (activating)
    modulator

    Interaction Info:
    Mechanism of Interaction Interleukin-2 receptor agonist
    Direct Interaction yes
    Trial Name Proleukin IL-2

    PMIDs:
    16596189 16617454 16542139 11752352 16569767 16477002


    Sources:
    TEND TdgClinicalTrial DrugBank ChemblInteractions

  • ALDESLEUKIN   IL2RG

    Interaction Score: 21.3

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Interleukin-2 receptor agonist
    Direct Interaction yes
    Trial Name Proleukin IL-2

    PMIDs:
    17598841 17635814 17083048 16477002 17363735


    Sources:
    TEND TdgClinicalTrial DrugBank ChemblInteractions

  • ALDESLEUKIN   IL2RA

    Interaction Score: 5.39

    Interaction Types & Directionality:
    agonist (activating)
    modulator

    Interaction Info:
    Novel drug target Established target
    Trial Name Proleukin IL-2
    Mechanism of Interaction Interleukin-2 receptor agonist

    PMIDs:
    17584597 16767920 10207608 16864089 11752352 17216565 17530023


    Sources:
    TEND TdgClinicalTrial DrugBank ChemblInteractions

  • ALDESLEUKIN   IL2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DrugBank: DB00041

    • Version: 5.1.7

    Alternate Names:
    ALDESLEUKIN DrugBank Drug Name
    110942-02-4 CAS Number
    Proleukin Drug Brand

    Drug Info:
    Drug Type biotech
    Drug Groups approved
    Drug Categories adjuvants, immunologic

    Publications:
    Vlad et al., 2007, Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation., Transpl. Immunol.
    Recchia et al., 2003, Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy., J. Exp. Clin. Cancer Res.
    Ouyang et al., 1999, Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes., Arch. Toxicol.

  • TEND: ALDESLEUKIN

    • Version: 01-August-2011

    Alternate Names:
    ALDESLEUKIN Primary Drug Name

    Drug Info:
    Year of Approval 1992
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: ALDESLEUKIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class recombinant protein
    FDA Approval approved

    Publications:

  • TTD: Aldesleukin

    • Version: 2020.06.01

    Alternate Names:
    D05PUD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201438

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201438

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21